The VISTA protein is known as being responsible for the resistance to anti-PD-1/anti-CTLA-4 treatments, reported in prostate cancer [54,55], with an overall success rate of 30% of these targeted therapies [17,28,56], suggesting that blocking VISTA could be a good strategy to improve patients’ prognosis. This evidence concerns the gene VSIR and Familial prostate cancer.